注射用复合辅酶在恶性肿瘤化疗支持治疗中的作用

The Role of Composite Coenzyme for Injection in Chemotherapy Support for Malignant Tumors

目的探讨注射用复合辅酶在恶性肿瘤化疗支持治疗中的作用。方法方便选取该院2017年1月—2018年10月收治的恶性肿瘤30例,按照随机数字表法分组,观察组15例,于化疗期间第1~5天行注射用复合辅酶(鑫贝科)静脉注射治疗,对照组15例,仅行化疗治疗;对两组治疗情况进行分析。结果①两组近期疗效比较差异无统计学意义(χ^2=0.19,P=0.666);②血液学毒性反应:观察组患者Ⅲ、Ⅳ度白细胞减少发生率为6.7%,对照组为40.0%,观察组均明显低于对照组(χ^2=4.66,P=0.031);两组Ⅲ、Ⅳ度贫血发生率为6.7%,对照组为26.7%,两组比较差异无统计学意义(χ^2=2.16,P=0.142);观察组中性粒细胞减少、血小板减少发生率分别为6.7%、6.7%,对照组分别为40.0%、40.0%,组间差异有统计学意义(χ^2=4.66、4.66,P=0.031、0.031);③胃肠道反应比较:两组食欲减退发生率、恶心、呕吐发生率分别为6.7%(1/15)、20.0%(3/15),对照组分别为4例(26.7%)、60.0%(9/15),组间比较食欲减退发生率差异无统计学意义(χ^2=2.16,P=0.142),恶心、呕吐发生率差异有统计学意义(χ^2=4.66,P=0.031);④观察组患者肝功能、肾功能损伤发生率分别为6.7%(1/15)、6.7%(1/15),对照组分别为40.0%(6/15)、26.7%(4/15),观察组肝功能损伤发生率明显低于对照组(χ^2=4.66,P=0.031),但肾功能损伤发生率则差异无统计学意义(χ^2=2.16,P=0.142)。结论注射用复合辅酶在恶性肿瘤化疗支持治疗中可发挥积极作用,对减少化疗毒副作用有重要价值。

Objective To investigate the role of composite coenzyme for injection in chemotherapy support for malignant tumors.Methods Thirty patients with malignant tumors admitted to our hospital from January 2017 to October 2018 were enrolled according to the random number table.15 patients in the observation group were convenient injected with compound coenzyme(Xinbec)vein for the first 1~5 days of chemotherapy injection treatment,15 cases in the control group,only chemotherapy treatment;analysis of the treatment of the two groups.Results 1.There was no significant difference between the two groups in the short-term efficacy(χ^2=0.19,P=0.666);2.Hematologic toxicity:the incidence of III and IV leukopenia in the observation group was 6.7%,and the control group was 40.0%,the observation group were significantly lower than the control group(χ^2=4.66,P=0.031);the incidence of III and IV anemia was 6.7%in the two groups,and 26.7%in the control group.There was no significant difference between the two groups(χ^2=2.16,P=0.142);the incidence of neutropenia and thrombocytopenia in the observation group were 6.7%and 6.7%,respectively,and that in the control group were 40.0%and 40.0%,respectively.The difference between the two groups was significant(χ^2=4.66,4.66,P=0.031,0.031);3.comparison of gastrointestinal reactions:the incidence of loss of appetite,nausea and vomiting in the two groups were 6.7%(1/15),20.0%(3/15),respectively,and the control group of 4 cases(26.7%)and 60.0%(9/15),there was no significant difference in the incidence of appetite loss between the groups(χ^2=2.16,P=0.142),and the incidence of nausea and vomiting was significantly different(χ^2=4.66,P=0.031).4.The incidence of liver function and renal function injury in the observation group were 6.7%(1/15)and 6.7%(1/15),respectively,and that in the control group were 40.0%(6/15),26.7%(4/15),the incidence of liver function injury in the observation group was significantly lower than that in the control group(χ^2=4.66,P=0.031),but the incidence of renal function injury was not significantly different(χ^2=2.16,P=0.142).Conclusion The composite coenzyme for injection can play an active role in chemotherapy support for malignant tumors,and it is of great value in reducing the side effects of chemotherapy.